<DOC>
	<DOCNO>NCT00779506</DOCNO>
	<brief_summary>This 8-week , multi-centre , Open-label , non-comparative study evaluate efficacy safety Quetiapine XR daily dose 400mg-800mg used mono-therapy treatment acute schizophrenic patient . The eligible patient assign study treatment Quetiapine XR Day 1 . PLEASE NOTE : Seroquel SR Seroquel XR refer formulation . The SR designation change XR consultation FDA .</brief_summary>
	<brief_title>Study Efficacy Safety Quetiapine Fumarate Extended Release ( Seroquel XR )</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Documented clinical diagnosis meeting Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV ) criterion PANSS total score least 70 enrolment assignment Day 1 CGI Severity Illness score least 4 ( moderately ill ) enrolment assignment Day 1 worsen patient 's condition 3 week Known intolerance lack response quetiapine fumarate Administration depot antipsychotic injection within one dose interval ( depot ) assignment Substance alcohol dependence enrolment Opiates , amphetamine , barbiturate , cocaine , cannabis , hallucinogen abuse DSMIV criterion within 4 week prior enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Acute schizophrenia</keyword>
	<keyword>PANSS</keyword>
</DOC>